p38 MAP kinase inhibitors: a future therapy for inflammatory diseases
RJ Mayer, JF Callahan - Drug Discovery Today: Therapeutic Strategies, 2006 - Elsevier
p38 mitogen-activated kinase is a target for therapeutic intervention in inflammatory
diseases. The pharmacology of p38 inhibitors is reviewed briefly, and potential other
therapeutic targets in this important signaling pathway are outlined. The evaluation of p38
inhibitors in early clinical studies is reviewed with emphasis on pharmacodymanic
assessment. Ex vivo and in vivo lipopolysaccharide (LPS) challenges have been successful
in Phase I studies and will be of value in the early assessment of future p38 inhibitors.
diseases. The pharmacology of p38 inhibitors is reviewed briefly, and potential other
therapeutic targets in this important signaling pathway are outlined. The evaluation of p38
inhibitors in early clinical studies is reviewed with emphasis on pharmacodymanic
assessment. Ex vivo and in vivo lipopolysaccharide (LPS) challenges have been successful
in Phase I studies and will be of value in the early assessment of future p38 inhibitors.